|
|
|
|
|
Symposium on Recent Advancements on Drug Discovery Science and Technology |
|
|
|
Symposium on Novel Drug Delivery Systems and Technology |
|
|
|
Symposium on New Discoveries and Achievements of Cancer Research |
|
|
|
Symposium on Latest Advances in Cardiovascular Research and Therapeutics Development |
|
|
|
Symposium on Innovation on CNS Research and Therapeutics Development |
|
|
|
Symposium on Updates on Diabetes Research and Therapy |
|
|
|
|
|
Online Registration is Open
October 1st, 2019 |
|
Call for speakers!
September 1st, 2019 |
|
Welcome to the website of WCDI-2021
August 15th, 2019 |
|
|
|
|
|
Abstract Submission Start Day
September 1st, 2019 |
|
Earlybird Registration Start Day
October 1st, 2019 |
|
Earlybird Registration Deadline
December 31st, 2019
|
|
Abstract Submission Deadline
June 30th, 2022
|
|
Acceptance Notification Deadline
July 20 th, 2022 |
|
|
|
|
|
|
Symposium on
New Discoveries and Achievements of Cancer Research |
|
|
Introduction |
Symposium on New Discoveries and Achievements of Cancer Research is dedicated to the professionals in cancer filed a multidisciplinary platform to learn about the latest scientific updates and current industry standards in cancer treatment. The aims of the Symposium are to provide a high quality program designed to attract delegates from all cancer research disciplines & anti-cancer medicine development, and encourage these researchers to interact and in some cases forge new collaborations. |
Topics |
Session 3-1: Emerging Scientific Discoveries in Oncology Research |
Session 3-2: Impact of Cutting-Edge Cancer Diagnostic Technologies |
Session 3-3: Market Potential of Promising Anti-Cancer Drugs in Pharma R&D Pipeline |
Session 3-4: Updates on Clinical Oncology |
Session 3-5: Trends in Cancer Precision Medicine |
Session 3-6: Latest Developments in Immuno-Oncology & Immunotherapy |
Session 3-7: Advances in Cancer Prevention, Screening and Control |
|
|
AGENDA
Day 0, August 11, 2021
Registration
Day 1, August 12, 2021
MORNING
Opening Ceremony
Welcome Remark by Honorary Chairs
Dr. Andreas Strasse, Fellow Of The Australian Academy of Science; NHMRC Senior Principal Research Fellow, Alan W Harris Personal Chair, Walter And Eliza Hall Institute of Medical Research, Australia
Dr. Chong-Su Cho, Fellow of Korean Academy of Science and Technology, Fellow of International Union of Societies for Biomaterials Science and Engineering; Research Professor, Research Institute for Agriculture and Life Sciences, Seoul National University, South Korea
|
|
|
Keynote Forum I for Drug Discovery
|
|
|
|
Call for Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
09:15-9:45 |
Title: GPCRomics: an approach to identify novel GPCR targets
Dr. Paul A. Insel, Distinguished Professor of Pharmacology and Distinguished Professor of Medicine, Co-Director, Medical Scientist (MD/PhD) Training Program, University of California, San Diego, USA |
|
|
09:45-10:15 |
Title: Inhibitors of Bruton’s tyrosine kinase (BTK) are transforming leukemia and lymphoma treatment
Dr. C. I. Edvard SMITH, Professor, Karolinska Institute, Sweden |
|
|
10:15-10:45 |
Title: Peptide Based Radiopahrmaceuticals for Cancer Diagnosis
Dr. Yueqing Gu, Professor, Biomedical Engineering; Dean, School of Engineering; Director, Molecular imaging
and Biomedical Engineering
China Pharmaceutical University, China |
|
|
10:45-11:00 |
Coffee Break |
|
|
11:00-11:30 |
Title: The Dawning of a New Era in Drug Discovery and Development
Dr. Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec, USA |
|
|
11:30-12:00 |
Speech Opportunity Available |
|
|
Day 1, August 12, 2021
AFTERNOON
|
|
Symposium 3: New Discoveries and Achievements of Cancer Research
|
|
|
|
Dr. Sun-Young Han, Professor, College of Pharmacy, Gyeongsang National University, South Korea |
|
|
Co-Chair |
Dr. Byoung S. Kwon, CEO, Eutilex Co Ltd., South Korea |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Speech Opportunity Available |
|
|
13:55-14:20 |
Speech Opportunity Available |
|
|
14:20-14:45 |
Title: Predicting Factors of Prostate Cancer Screening Behavior
Dr. Park, Jin Hee, Department of Nursing, Changshin University, Republic of Korea |
|
|
14:45-15:10 |
Title: TBD
Dr. Byoung S. Kwon, CEO, Eutilex Co Ltd., South Korea |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|